Blog January 21, 2016

Increasing Role for Biomarkers in R&D, Clinical Medicine, and Pharma Marketing

Bionest team member Rachel Laing recently contributed to a feature in the January issue of PharmaVoice PV0116_PharmaRDisNowon the growing role and prominence of biomarker strategies in drug development and commercialization. In addition to helping to better identify those patients who will respond to a particular therapy, a biomarker strategy enables companies to differentiate their product and themselves in a highly competitive market. In cancer, and increasingly other indications, a well-validated biomarker for efficacy provides physicians, patients, and payers with a higher degree of certainty that the treatment will work in a specific patient population and helps to demonstrate value — an increasingly important attribute in this era of growing attention to drug pricing and therapeutic benefit.